HIV Evolution, Epidemiology and Prevention

Group Leader

Nuno Taveira

PhD (1996) in Pharmacy (Microbiology), Universidade de Lisboa
Research Associate, IMed.ULisboa, Faculty of Pharmacy of University of Lisbon; Full Professor (Microbiology and Molecular Biology), Instituto Superior de Ciências da Saúde Egas Moniz (ISCSEM), Caparica.

 

The Research

Grupo NTaveira

We sequence the full-length or partial genomes of HIV-1, HIV-2 and more recently Yellow Fever virus, and use phylogenetic analysis and resistance mutation analysis to characterize the epidemiology, transmission dynamics, diversity and evolution of these viruses in Portugal, Angola, Mozambique and Cape Verde. The epidemiologic data contributes for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), Institute of Health Metrics and Evaluation, Washington, USA. The information on virus diversity is translated into the production/validation of new diagnosis tests, implementation of better treatment regimens, and development of new vaccine candidates. We also perform the pre-clinical evaluation of new vaccine and microbicide candidates and new drugs for the treatment, prevention and cure of HIV infection.

Image_Research_HIV_Group

 

Ongoing Projects

Source: Fundação Luso-Americana para o Desenvolvimento (Luso-American Collaborative Response Award on HIV/AIDS)
Title: HIV-2 epidemiology, drug resistance and pathogenesis in Cape Verde: the Cape Verde HIV-2 Cohort
PI: Klaus Strebel
Period: Open

Source: NIH, USA (R-00260-15-0)
Title: Reconstructing HIV epidemics from HIV phylogenetics.
PI: Thomas Leitner, Los Alamos National Lab, USA
Period: 2014-2019

Source: Gileads Sciences (GÉNESE Program, 2015)
Title: Induction of neutralizing antibodies in rabbits with a new type of HIV-1 vaccine.
PI: Nuno Taveira, Egas Moniz, CRL
Period: 2016-2018

Source: Bristol Meyers Squibb (BMS Partnering for cure Program)
Title: Gene therapies for HIV cure using RNA replicons targeting HIV entry and latency.
PI: Pedro Borrego, iMEd.ULisboa
Period: 2015-2017

Source: Gilead Sciences (GÉNESE Program, 2014)
Title: COMBI-VIH: nanoplatform for the modulation of immune cells for the control of HIV infection
PI: Helena Florindo, iMEd.ULisboa
Period: 2015-2017

Recent Most Relevant Publications

Verónica Briz, Daniel Sepúlveda-Crespo, Ana Rita Diniz,  et al. 2015. Development  of  water-soluble  polyanionic  carbosilane  dendrimers as novel and highly potent topical anti-HIV-2 microbicides. Nanoscale, 35:14669-83.

Palladino C, Gómez ML, Soler-Palacín P, et al. 2015. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS, 29(16):2155-9.

Inês Bártolo, Susana Zakovic, Francisco Martin, et al. 2014. HIV-1 Diversity, Transmission Dynamics and Primary Drug Resistance in Angola. PLoS ONE. 9(12):e113626. doi: 10.1371/journal.pone.0113626. IF: 3.7

Borrego P, Calado R, Marcelino JM, et al. 2013. An ancestral HIV-2/SIV peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. AIDS. 27: 1081-1090.

Marcelino JM, Borrego P, Nilsson C,  et al. 2012. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. AIDS. 26: 2275-2284.

Group Members

Master Students

  • Ifeanyi Jude Ezeonwumelu
  • Susana Tracana